{
 "cells": [
  {
   "cell_type": "code",
   "execution_count": 56,
   "id": "bdc25a86",
   "metadata": {},
   "outputs": [],
   "source": [
    "import requests\n",
    "import pyobo\n",
    "from langchain_ollama import chat_models, ChatOllama,OllamaEmbeddings\n",
    "from langchain.agents.middleware import dynamic_prompt,wrap_model_call,wrap_model_call,ModelRequest,ModelResponse,SummarizationMiddleware\n",
    "import scispacy\n",
    "import spacy\n",
    "import faiss\n",
    "import requests\n",
    "from langchain.agents import create_agent\n",
    "from langgraph.checkpoint.memory import InMemorySaver\n",
    "from typing import List,Literal,Optional\n",
    "from lxml import etree as ET \n",
    "from langchain_community.document_loaders import WebBaseLoader\n",
    "from bs4 import BeautifulSoup\n",
    "from langchain_community.docstore.in_memory import InMemoryDocstore\n",
    "from langchain_community.vectorstores import FAISS\n",
    "from langchain_core.documents import Document\n",
    "import re\n",
    "from langchain_text_splitters import RecursiveCharacterTextSplitter"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "97dbbc35",
   "metadata": {},
   "outputs": [],
   "source": [
    "#linker = pyobo.get_scispacy_entity_linker(\"uniprot\", filter_for_definitions=False, resolve_abbreviations=True)\n",
    "nlp = spacy.load('en_ner_jnlpba_md')\n",
    "nlp.add_pipe(\"sentencizer\")\n",
    "linker = pyobo.get_scispacy_entity_linker(\"hgnc\", filter_for_definitions=False, resolve_abbreviations=True,)\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 11,
   "id": "4301cbff",
   "metadata": {},
   "outputs": [],
   "source": [
    "def pubmed_query(\n",
    "    include_topics: List[str],\n",
    "    operator: Literal[\"AND\", \"OR\"] = \"AND\",\n",
    "    exclude_topics: Optional[List[str]] = None,\n",
    "    publication_type: Optional[Literal[\"review\", \"article\"]] = None,\n",
    "    organism: Optional[str] = None,\n",
    "    journal: Optional[str] = None,\n",
    "    start_year: Optional[int] = None,\n",
    "    end_year: Optional[int] = None,\n",
    "    free_full_text: bool = True\n",
    ") -> str:\n",
    "    \"\"\"\n",
    "    Build a simple, elegant PubMed query.\n",
    "    \"\"\"\n",
    "\n",
    "    clauses = []\n",
    "\n",
    "    # Automatic free full text\n",
    "    if free_full_text:\n",
    "        clauses.append(\"free full text[filter]\")\n",
    "\n",
    "    # Include topics\n",
    "    if include_topics:\n",
    "        topic_clause = \" OR \".join([f'\"{t}\"[Title/Abstract]' for t in include_topics])\n",
    "        if len(include_topics) > 1:\n",
    "            topic_clause = f'({topic_clause})'\n",
    "        clauses.append(topic_clause)\n",
    "\n",
    "    # Publication type\n",
    "    if publication_type:\n",
    "        pt_map = {\"review\": \"review[Publication Type]\", \"article\": \"journal article[Publication Type]\"}\n",
    "        clauses.append(pt_map.get(publication_type.lower(), \"\"))\n",
    "\n",
    "    # Organism\n",
    "    if organism:\n",
    "        org_map = {\"human\": \"humans[MeSH Terms]\", \"mouse\": \"mice[MeSH Terms]\", \"rat\": \"rats[MeSH Terms]\"}\n",
    "        clauses.append(org_map.get(organism.lower(), f'\"{organism}\"[MeSH Terms]'))\n",
    "\n",
    "    # Journal\n",
    "    if journal:\n",
    "        clauses.append(f'\"{journal}\"[Journal]')\n",
    "\n",
    "    # Date range\n",
    "    if start_year and end_year:\n",
    "        clauses.append(f'(\"{start_year}\"[Date - Publication] : \"{end_year}\"[Date - Publication])')\n",
    "    elif start_year:\n",
    "        clauses.append(f'\"{start_year}\"[Date - Publication]')\n",
    "    elif end_year:\n",
    "        clauses.append(f'\"{end_year}\"[Date - Publication]')\n",
    "\n",
    "    # Exclude topics\n",
    "    if exclude_topics:\n",
    "        for t in exclude_topics:\n",
    "            clauses.append(f'NOT \"{t}\"[Title/Abstract]')\n",
    "\n",
    "    # Combine clauses with AND\n",
    "    return \" AND \".join(clauses)\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 12,
   "id": "bca26079",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "'free full text[filter] AND (\"AKT signaling\"[Title/Abstract] OR \"wnt signalling\"[Title/Abstract]) AND review[Publication Type] AND humans[MeSH Terms] AND (\"2024\"[Date - Publication] : \"2025\"[Date - Publication])'"
      ]
     },
     "execution_count": 12,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "query = pubmed_query(\n",
    "    include_topics=[\"AKT signaling\",'wnt signalling'],\n",
    "    publication_type=\"review\",\n",
    "    organism=\"Human\",\n",
    "    start_year=2024,\n",
    "    end_year=2025\n",
    ")\n",
    "query"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 16,
   "id": "03fe835f",
   "metadata": {},
   "outputs": [],
   "source": [
    "def fetch_ncbi_data(query):\n",
    "    base_url_esearch='https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esearch.fcgi'\n",
    "    params_esearch = {\"db\": \"pubmed\",\"term\": query,\"retmode\": \"json\",\"retstart\": 0,\"retmax\": 10000,'email':'your_email@example.com',\n",
    "              'datetype':'pdat'}\n",
    "    response_esearch=requests.get(base_url_esearch, params=params_esearch)\n",
    "    list_of_pubmed=response_esearch.json()['esearchresult']['idlist']\n",
    "    dois=[]\n",
    "    journal=[]\n",
    "    pmcids=[]\n",
    "    base_pmc = 'https://www.ncbi.nlm.nih.gov/pmc/articles/'\n",
    "    base_url_efetch='https://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi'\n",
    "    for list in [list_of_pubmed[i:i+10]for i in range(0,len(list_of_pubmed),10)]:\n",
    "        query=f\"https://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi\"\n",
    "        param_efetch={'retmode':'xml',\"db\": \"pubmed\",\"id\": ','.join(list),\"retstart\": 0,\"retmax\": 1000}\n",
    "        response_efetch=requests.get(base_url_efetch,params=param_efetch)\n",
    "        tree = ET.fromstring(response_efetch.text)\n",
    "        base='https://doi.org/'\n",
    "        for i in tree.findall('PubmedArticle/PubmedData/ArticleIdList/ArticleId'):\n",
    "            if i.attrib.get('IdType')=='doi':\n",
    "                dois.append(base+i.text)\n",
    "            elif i.attrib.get('IdType') == 'pmc':   # ✅ added\n",
    "                pmcids.append(base_pmc + i.text)\n",
    "        for i in tree.findall('PubmedArticle/MedlineCitation/Article/Journal/Title'):\n",
    "            journal.append(i.text)\n",
    "            \n",
    "    return dois, journal,pmcids\n",
    "            "
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 17,
   "id": "5077a574",
   "metadata": {},
   "outputs": [],
   "source": [
    "dois, journal,pmcids=fetch_ncbi_data(query)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 22,
   "id": "e60b3061",
   "metadata": {},
   "outputs": [],
   "source": [
    "def load_doi_page_raw(url: str):\n",
    "    loader = WebBaseLoader(\n",
    "        web_paths=[url],\n",
    "        header_template={\n",
    "            \"User-Agent\": (\n",
    "                \"Mozilla/5.0 (X11; Linux x86_64) \"\n",
    "                \"AppleWebKit/537.36 (KHTML, like Gecko) \"\n",
    "                \"Chrome/120.0 Safari/537.36\"\n",
    "            )\n",
    "        },\n",
    "    )\n",
    "    docs = loader.load()\n",
    "    return docs[0]\n",
    "\n",
    "def extract_main_article_text(html_text: str) -> str:\n",
    "    soup = BeautifulSoup(html_text, \"lxml\")\n",
    "\n",
    "    # Remove junk\n",
    "    for tag in soup([\n",
    "        \"script\", \"style\", \"noscript\", \"svg\",\n",
    "        \"header\", \"footer\", \"nav\", \"aside\",\n",
    "        \"form\", \"button\"\n",
    "    ]):\n",
    "        tag.decompose()\n",
    "\n",
    "    text = soup.get_text(separator=\"\\n\")\n",
    "\n",
    "    # Normalize whitespace\n",
    "    text = re.sub(r\"\\n{3,}\", \"\\n\\n\", text)\n",
    "    text = re.sub(r\"[ \\t]+\", \" \", text)\n",
    "\n",
    "    return text.strip()\n",
    "\n",
    "def build_clean_document(raw_doc: Document) -> Document:\n",
    "    clean_text = extract_main_article_text(raw_doc.page_content)\n",
    "\n",
    "    return Document(\n",
    "        page_content=clean_text,\n",
    "        metadata={\n",
    "            **raw_doc.metadata,\n",
    "            \"source_type\": \"doi_webpage\",\n",
    "            \"cleaned\": True,\n",
    "        }\n",
    "    )\n",
    "def load_full_article_from_doi(url: str) -> Document:\n",
    "    raw_doc = load_doi_page_raw(url)\n",
    "    clean_doc = build_clean_document(raw_doc)\n",
    "    return clean_doc\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 23,
   "id": "df141d83",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "\"headers = {\\n    'User-Agent': 'Mozilla/5.0 (Windows NT 10.0; Win64; x64) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/102.0.0.0 Safari/537.36',\\n}\\nall_docs=[]\\nfor i in tqdm(doi): \\n    try:\\n        doc=load_full_article_from_doi(i)\\n        if len(doc.page_content)>1000:\\n            all_docs.append(doc)\\n    except Exception as e:\\n        print(e)\\n        continue\""
      ]
     },
     "execution_count": 23,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "headers = {\n",
    "    'User-Agent': 'Mozilla/5.0 (Windows NT 10.0; Win64; x64) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/102.0.0.0 Safari/537.36',\n",
    "}\n",
    "all_docs=[]\n",
    "for i in pmcids: \n",
    "    try:\n",
    "        doc=WebBaseLoader(i,continue_on_failure=True,requests_kwargs={'allow_redirects': True,\n",
    "                                            \"headers\": headers}).load()[0]\n",
    "        if len(doc.page_content)>2000:\n",
    "            all_docs.append(doc)\n",
    "    except Exception as e:\n",
    "        print(e)\n",
    "        continue\n",
    "    \n",
    "    \n",
    "\"\"\"headers = {\n",
    "    'User-Agent': 'Mozilla/5.0 (Windows NT 10.0; Win64; x64) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/102.0.0.0 Safari/537.36',\n",
    "}\n",
    "all_docs=[]\n",
    "for i in tqdm(doi): \n",
    "    try:\n",
    "        doc=load_full_article_from_doi(i)\n",
    "        if len(doc.page_content)>1000:\n",
    "            all_docs.append(doc)\n",
    "    except Exception as e:\n",
    "        print(e)\n",
    "        continue\"\"\"\n",
    "\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 25,
   "id": "81b37a58",
   "metadata": {},
   "outputs": [],
   "source": [
    "def extract_main_content(text: str) -> Optional[str]:\n",
    "    \n",
    "    abstract_pat = r'\\babstract\\b'\n",
    "    intro_pat = r'\\bintroduction\\b'\n",
    "    ref_pat = r'\\breferences?\\b'\n",
    "    ack_pat = r'\\backnowledgment*\\b'\n",
    "    \n",
    "    text=re.sub(r\"\\s*\\(?\\s*(?:Figure|Fig\\.?)\\s*[\\d.]+\\s*\\)?\\s*\",'',text,flags=re.IGNORECASE).strip()\n",
    "    text = re.sub(r'\\n{3,}', '\\n\\n', text)\n",
    "    text=re.sub('Open in a new tab','',text)\n",
    "\n",
    "    start_matches = list(re.finditer(intro_pat, text, re.IGNORECASE))\n",
    "    if not start_matches:\n",
    "        start_matches = list(re.finditer(abstract_pat, text, re.IGNORECASE))\n",
    "\n",
    "    end_matches = list(re.finditer(ack_pat, text, re.IGNORECASE))\n",
    "    if not end_matches:\n",
    "        end_matches = list(re.finditer(ref_pat, text, re.IGNORECASE))\n",
    "\n",
    "    if not start_matches or not end_matches:\n",
    "        return None\n",
    "\n",
    "    candidates = []\n",
    "\n",
    "    for start in start_matches:\n",
    "        for end in end_matches:\n",
    "            if end.start() > start.start():\n",
    "                span = text[start.start():end.start()].strip()\n",
    "                if len(span) > 300:\n",
    "                    candidates.append(span)\n",
    "\n",
    "    if not candidates:\n",
    "        return None\n",
    "\n",
    "    return max(candidates, key=len)\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 26,
   "id": "c108592b",
   "metadata": {},
   "outputs": [],
   "source": [
    "cleaned_docs=[]\n",
    "for doc in all_docs:\n",
    "    text=extract_main_content(doc.page_content)\n",
    "    if text and len(text)>2000:\n",
    "        cleaned_nlp=linker(nlp(text))\n",
    "        new_text=text\n",
    "        for i in reversed(cleaned_nlp.ents):\n",
    "            id=i._.kb_ents\n",
    "            if id:\n",
    "                name=linker.kb.cui_to_entity[id[0][0]].canonical_name\n",
    "                new_text = new_text[:i.start_char] + name + ' ' + i.label_ + new_text[i.end_char:]\n",
    "        cleaned_nlp=linker(nlp(new_text))\n",
    "        text=''.join([i.text for i in cleaned_nlp.sents])\n",
    "        doc.page_content=text\n",
    "        cleaned_docs.append(doc)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 38,
   "id": "44cb432c",
   "metadata": {},
   "outputs": [],
   "source": [
    "splitter = RecursiveCharacterTextSplitter(chunk_size=1024,chunk_overlap=256,length_function=len)\n",
    "chunks=splitter.split_documents(cleaned_docs)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "230263d1",
   "metadata": {},
   "outputs": [],
   "source": [
    "embeddings_model = OllamaEmbeddings(model=\"qwen3-embedding:0.6b\",validate_model_on_init=True,num_thread=2)\n",
    "embedding_dim = len(embeddings_model.embed_query(\"hello world\"))\n",
    "index = faiss.IndexFlatL2(embedding_dim)\n",
    "\n",
    "vector_store = FAISS(\n",
    "    embedding_function=embeddings_model,\n",
    "    index=index,\n",
    "    docstore=InMemoryDocstore(),\n",
    "    index_to_docstore_id={},\n",
    ")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 43,
   "id": "9adc49c3",
   "metadata": {},
   "outputs": [],
   "source": [
    "ids = vector_store.add_documents(documents=chunks)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 44,
   "id": "e34b8051",
   "metadata": {},
   "outputs": [],
   "source": [
    "vector_store.save_local(\"/home/bionik/AI_ML/FDA_Project/LLM/faiss_index\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 2,
   "id": "252be7f8",
   "metadata": {},
   "outputs": [],
   "source": [
    "embeddings_model = OllamaEmbeddings(model=\"qwen3-embedding:0.6b\",validate_model_on_init=True)\n",
    "\n",
    "vector_store = FAISS.load_local(\n",
    "    \"/home/bionik/AI_ML/FDA_Project/LLM/faiss_index\",\n",
    "    embeddings_model,\n",
    "    allow_dangerous_deserialization=True \n",
    ")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 45,
   "id": "9154549c",
   "metadata": {},
   "outputs": [],
   "source": [
    "LLM_model = ChatOllama(num_ctx=10000,model=\"qwen3:4b-instruct-2507-q4_K_M\",validate_model_on_init=True)\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "3bf420f2",
   "metadata": {},
   "outputs": [],
   "source": [
    "# -------------------------------\n",
    "# 3️⃣ Retrieval Middleware\n",
    "# -------------------------------\n",
    "@dynamic_prompt\n",
    "def retrieve_context_middleware(request: ModelRequest) -> str:\n",
    "    \"\"\"\n",
    "    Always rewrites the user query using conversation history,\n",
    "    overwrites the human message, and retrieves context using the\n",
    "    rewritten query.\n",
    "    \"\"\"\n",
    "\n",
    "    # -------------------------------\n",
    "    # 1️⃣ Extract original query + history\n",
    "    # -------------------------------\n",
    "    messages = request.state[\"messages\"]\n",
    "    original_query = messages[-1].content.strip()\n",
    "\n",
    "    history = \"\\n\".join(\n",
    "        m.content for m in messages[:-1]\n",
    "        if m.type in {\"human\", \"ai\"}\n",
    "    )\n",
    "\n",
    "    # -------------------------------\n",
    "    # 2️⃣ Rewrite query deterministically (NOT a tool)\n",
    "    # -------------------------------\n",
    "    # -------------------------------\n",
    "    # 2️⃣ Classify question early (for rewrite strategy)\n",
    "    # -------------------------------\n",
    "    classify_prompt = f\"\"\"\n",
    "Classify the following life sciences or healthcare research question.\n",
    "\n",
    "Return ONLY one word:\n",
    "\n",
    "FACTUAL → asks for established biological knowledge, known mechanisms,\n",
    "           experimentally observed effects, reported associations,\n",
    "           pathway descriptions, molecular functions, or clinical findings.\n",
    "\n",
    "REASONING → asks for interpretation, causal explanation, prediction,\n",
    "            intervention outcomes, perturbation effects, mechanistic inference,\n",
    "            hypothesis generation, or answers requiring extrapolation beyond\n",
    "            directly reported evidence.\n",
    "\n",
    "Question:\n",
    "\"{original_query}\"\n",
    "\"\"\"\n",
    "\n",
    "    qtype_for_rewrite = LLM_model.invoke(classify_prompt).content.strip().upper()\n",
    "    request.state[\"qtype\"] = qtype_for_rewrite\n",
    "\n",
    "    # -------------------------------\n",
    "    # 3️⃣ Rewrite query deterministically (NOT a tool)\n",
    "    # -------------------------------\n",
    "    if qtype_for_rewrite == \"REASONING\":\n",
    "        rewrite_prompt = f\"\"\"\n",
    "Rewrite the following biomedical question to optimize literature retrieval\n",
    "for mechanistic reasoning and hypothesis generation.\n",
    "\n",
    "Rules (STRICT):\n",
    "- Preserve the scientific intent of the user’s question.\n",
    "- Treat the question as implicitly referring to the biological context\n",
    "  established in the conversation history.\n",
    "- DO NOT add topic of your own in query unless explicitly asked.\n",
    "- If the question is generic (e.g., \"why\", \"how\", \"what happens\"),\n",
    "  reinterpret it as applying specifically to the entities, mechanisms,\n",
    "  or biological systems discussed previously.\n",
    "- Anchor the rewritten query to the SAME biological focus as the history.\n",
    "- Do NOT introduce new example entities to illustrate the answer.\n",
    "- Do NOT broaden to unrelated genes, proteins, pathways, or diseases.\n",
    "- If generalization is required, restrict it to:\n",
    "  the same molecular role, functional class, or mechanistic process\n",
    "  already implied by the context — without naming new entities.\n",
    "- Prefer standardized biomedical terminology.\n",
    "- Expand abbreviations where appropriate.\n",
    "- Do NOT include speculative language in the query itself.\n",
    "- Return ONLY the rewritten query.\n",
    "\n",
    "Conversation history:\n",
    "{history}\n",
    "\n",
    "Original question:\n",
    "{original_query}\n",
    "\n",
    "\"\"\"\n",
    "    else:  # FACTUAL\n",
    "        rewrite_prompt = f\"\"\"\n",
    "Rewrite the following biomedical question for precise literature retrieval.\n",
    "\n",
    "Rules (STRICT):\n",
    "- Preserve the original meaning exactly.\n",
    "- Interpret the question in the context of the prior conversation.\n",
    "- Retain and emphasize the specific biological entities, mechanisms,\n",
    "  or systems already discussed.\n",
    "- Do NOT generalize beyond what is explicitly or contextually specified.\n",
    "- Do NOT introduce new entities.\n",
    "- Prefer standardized biomedical terminology.\n",
    "- Expand abbreviations if useful.\n",
    "- If already optimal, return unchanged.\n",
    "- Return ONLY the rewritten query.\n",
    "\n",
    "Conversation history:\n",
    "{history}\n",
    "\n",
    "Original question:\n",
    "{original_query}\n",
    "\n",
    "\"\"\"\n",
    "\n",
    "    rewritten_query = LLM_model.invoke(rewrite_prompt).content.strip()\n",
    "\n",
    "\n",
    "    # -------------------------------\n",
    "    # 3️⃣ Overwrite human message (critical)\n",
    "    # -------------------------------\n",
    "    messages[-1].content = rewritten_query\n",
    "\n",
    "    # Save both for transparency / debugging\n",
    "    request.state[\"original_query\"] = original_query\n",
    "    request.state[\"rewritten_query\"] = rewritten_query\n",
    "\n",
    "    # -------------------------------\n",
    "    # 4️⃣ Retrieve using rewritten query\n",
    "    # -------------------------------\n",
    "    docs = vector_store.max_marginal_relevance_search(rewritten_query,k=15,fetch_k=30)\n",
    "\n",
    "    sources = \"\\n\\n\".join(\n",
    "        f\"[SOURCE {i+1} research paper: {d.metadata.get('source','UNKNOWN')}]\\n{d.page_content}\"\n",
    "        for i, d in enumerate(docs)\n",
    "    )\n",
    "\n",
    "    # -------------------------------\n",
    "    # 5️⃣ Store retrieved context\n",
    "    # -------------------------------\n",
    "    request.state[\"retrieved_context\"] = sources\n",
    "\n",
    "    return \"\"\n",
    "\n",
    "\n",
    "@wrap_model_call\n",
    "def dynamic_model_selection(request: ModelRequest, handler) -> ModelResponse:\n",
    "    \"\"\"\n",
    "    Dynamically select model based on query type (FACTUAL vs REASONING).\n",
    "    \"\"\"\n",
    "\n",
    "    qtype = request.state.get(\"qtype\", \"FACTUAL\")\n",
    "    if qtype == \"REASONING\":\n",
    "        print(f\"using REASONING LLM for answering\")\n",
    "        LLM_model = ChatOllama(\n",
    "            name=\"reasoning\",\n",
    "            model=\"qwen3:4b-thinking-2507-q4_K_M\",\n",
    "            num_ctx=10000,\n",
    "            reasoning=True,\n",
    "        )\n",
    "    else:  # FACTUAL\n",
    "        print(f\"using FACTUAL LLM for answering\")\n",
    "        LLM_model = ChatOllama(\n",
    "            name=\"fact\",\n",
    "            model=\"qwen3:4b-instruct-2507-q4_K_M\",\n",
    "            num_ctx=10000)\n",
    "\n",
    "    return handler(request.override(model=LLM_model))   \n",
    "\n",
    "# -------------------------------\n",
    "# 4️⃣ Dynamic System Prompt\n",
    "# -------------------------------\n",
    "@dynamic_prompt\n",
    "def rag_system_prompt(request: ModelRequest) -> str:\n",
    "    messages = request.state[\"messages\"]\n",
    "    user_question = messages[-1].content.strip()\n",
    "    context = request.state.get(\"retrieved_context\", \"NO_RELEVANT_SOURCES_FOUND\")\n",
    "    history = \"\\n\".join(\n",
    "        m.content for m in messages[:-1] if m.type in {\"human\", \"ai\"}\n",
    "    )\n",
    "\n",
    "    # -----------------------\n",
    "    # Query classification\n",
    "    # -----------------------\n",
    "    classify_prompt = f\"\"\"\n",
    "Classify the following biomedical question.\n",
    "\n",
    "Return ONLY one word:\n",
    "FACTUAL  -> asks for known mechanisms or established facts\n",
    "REASONING -> asks about consequences, interventions, or what-if scenarios\n",
    "\n",
    "Question:\n",
    "\"{user_question}\"\n",
    "\"\"\"\n",
    "    qtype = LLM_model.invoke(classify_prompt).content.strip().upper()\n",
    "    request.state[\"qtype\"] = qtype\n",
    "    ## add dynamic_model_selection here\n",
    "    # -----------------------\n",
    "    # Mode-specific instructions\n",
    "    # -----------------------\n",
    "    if qtype == \"FACTUAL\":\n",
    "        mode_instruction = \"\"\"\n",
    "FACTUAL MODE (LIFE SCIENCES / HEALTHCARE):\n",
    "\n",
    "Objective:\n",
    "Provide a complete, authoritative, evidence-based explanation grounded in\n",
    "published biomedical literature.\n",
    "\n",
    "Rules:\n",
    "- Use retrieved SOURCES as the primary and preferred evidence.\n",
    "- Describe mechanisms, pathways, molecular interactions, phenotypic effects,\n",
    "  experimental results, or clinical observations exactly as reported.\n",
    "- Cover relevant biological detail thoroughly when supported by SOURCES.\n",
    "\n",
    "General biomedical knowledge:\n",
    "- May be used ONLY when necessary to complete an explanation.\n",
    "- Must be explicitly labeled as:\n",
    "  \"General biomedical knowledge (not from retrieved sources):\"\n",
    "- Must be textbook-level, widely accepted, and non-speculative.\n",
    "- Must not contradict retrieved SOURCES.\n",
    "\n",
    "Restrictions:\n",
    "- Do NOT introduce hypotheses, predictions, or inferred outcomes.\n",
    "- Do NOT generalize beyond what the evidence supports.\n",
    "- Do NOT add commentary about evidence sufficiency unless explicitly asked.\n",
    "\n",
    "Citations:\n",
    "- Every factual claim must be cited.\n",
    "- Use inline citations as [SOURCE X] with DOI or URL.\n",
    "\n",
    "\"\"\"\n",
    "    else:  # REASONING\n",
    "        mode_instruction = \"\"\"\n",
    "REASONING MODE (BIOLOGICAL INFERENCE & HYPOTHESIS GENERATION):\n",
    "\n",
    "Objective:\n",
    "Generate biologically plausible hypotheses and mechanistic explanations by\n",
    "connecting patterns across existing biomedical evidence.\n",
    "\n",
    "Evidence handling:\n",
    "- Ground all known facts in retrieved SOURCES and cite them as [SOURCE X].\n",
    "- When direct evidence for the exact query is limited or absent, you MAY:\n",
    "  - Identify mechanistically analogous, functionally related, or biologically\n",
    "    comparable evidence present in the SOURCES.\n",
    "  - Reason across shared biological roles, conserved mechanisms, or similar\n",
    "    perturbation effects implied by the literature.\n",
    "\n",
    "Hypothesis construction:\n",
    "- Hypotheses must be logically derived from cited evidence or established biology.\n",
    "- Clearly label all inferred or predictive statements as:\n",
    "  \"Hypothesis:\"\n",
    "- Hypotheses must remain biologically consistent and non-contradictory.\n",
    "- Do NOT present hypotheses as established facts.\n",
    "\n",
    "General biomedical knowledge:\n",
    "- May be used to support reasoning when necessary.\n",
    "- Must be explicitly labeled as:\n",
    "  \"General biomedical knowledge (not from retrieved sources):\"\n",
    "\n",
    "Restrictions:\n",
    "- Do NOT invent data, mechanisms, or citations.\n",
    "- Do NOT extrapolate beyond biologically reasonable inference.\n",
    "- Do NOT introduce unrelated biological domains.\n",
    "\n",
    "Citations:\n",
    "- Cite all evidence-based statements and reasoning anchors as [SOURCE X]\n",
    "  with DOI or URL.\n",
    "\n",
    "\"\"\"\n",
    "\n",
    "    # -----------------------\n",
    "    # Final system prompt\n",
    "    # -----------------------\n",
    "    return f\"\"\"\n",
    "You are a biomedical research assistant.\n",
    "\n",
    "Global rules:\n",
    "- Prefer retrieved SOURCES over general knowledge.\n",
    "- Never invent citations.\n",
    "- If evidence is insufficient, say so explicitly.\n",
    "- Provide links to all SOURCES at the end of the answer.\n",
    "\n",
    "Question type: {qtype}\n",
    "\n",
    "User question:\n",
    "{user_question}\n",
    "\n",
    "Conversation history:\n",
    "{history}\n",
    "\n",
    "Retrieved SOURCES:\n",
    "{context}\n",
    "\n",
    "{mode_instruction}\n",
    "\n",
    "Produce a clear, structured, citation-grounded answer.\n",
    "\"\"\"\n",
    "\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 57,
   "id": "72e54ead",
   "metadata": {},
   "outputs": [],
   "source": [
    "checkpointer = InMemorySaver()\n",
    "\n",
    "agent = create_agent(\n",
    "    model=LLM_model,\n",
    "    tools=[],\n",
    "    checkpointer=checkpointer,\n",
    "    middleware=[\n",
    "        retrieve_context_middleware,  # always inject retrieved context\n",
    "        rag_system_prompt,# dynamic prompt\n",
    "        dynamic_model_selection,#  dynamic model\n",
    "        SummarizationMiddleware(\n",
    "            model=LLM_model,\n",
    "            trigger=(\"tokens\", 7000),\n",
    "            keep=(\"messages\", 10),\n",
    "        ),\n",
    "    ],\n",
    ")\n",
    "\n",
    "\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 58,
   "id": "59983cbe",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "using FACTUAL LLM for answering\n",
      "Epidermal growth factor receptor (EGFR) signaling is activated through the binding of its ligand, epidermal growth factor (EGF), to the extracellular domain of the EGFR protein. This interaction induces a conformational change in the receptor, leading to autophosphorylation of specific tyrosine residues within its intracellular domain [SOURCE 11].\n",
      "\n",
      "The activation process begins when EGF, a single-chain polypeptide, binds to the extracellular domain of EGFR [SOURCE 11]. This binding induces a conformational change that promotes receptor dimerization—either homodimerization (EGFR-EGFR) or heterodimerization with other members of the ErbB family (e.g., HER2, HER3) [SOURCE 7]. Dimerization facilitates autophosphorylation of tyrosine residues in the intracellular kinase domain of EGFR, which activates its intrinsic tyrosine kinase activity [SOURCE 7].\n",
      "\n",
      "Once activated, the phosphorylated EGFR creates docking sites for intracellular signaling proteins, such as GRB2 (growth factor receptor-bound protein 2), which then recruits and activates downstream effectors like Son of Sevenless (SOS), a guanine nucleotide exchange factor (GEF) [SOURCE 5]. SOS facilitates the activation of Ras by promoting the exchange of GDP for GTP, thereby initiating the Ras/MAPK signaling cascade [SOURCE 5]. This cascade leads to the sequential activation of MEK1/2 (MAPK kinase) and ERK1/2 (MAPK), which translocate to the nucleus and phosphorylate transcription factors such as FOS and MYC, promoting gene expression related to cell proliferation, survival, and differentiation [SOURCE 5].\n",
      "\n",
      "Additionally, EGFR activation can also initiate the PI3K/AKT signaling pathway. Upon phosphorylation, the EGFR recruits the PI3K regulatory subunit p85α, which facilitates the activation of the PI3K catalytic subunit (PIK3CA) [SOURCE 13]. This results in the conversion of phosphatidylinositol-4,5-bisphosphate (PIP2) to phosphatidylinositol-3,4,5-trisphosphate (PIP3), which recruits AKT to the cell membrane. AKT is then phosphorylated and activated by phosphoinositide-dependent kinase 1 (PDK1) and mTORC2, promoting cell growth and survival [SOURCE 2].\n",
      "\n",
      "These signaling pathways are interconnected and contribute to diverse cellular outcomes, including proliferation, migration, and survival. The activation of EGFR signaling is tightly regulated and is often dysregulated in diseases such as cancer, where elevated ligand levels or receptor overexpression can lead to constitutive signaling [SOURCE 11].\n",
      "\n",
      "**References**  \n",
      "[SOURCE 1] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12308251  \n",
      "[SOURCE 7] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12548077  \n",
      "[SOURCE 5] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12595317  \n",
      "[SOURCE 11] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11506588  \n",
      "[SOURCE 13] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12571992  \n",
      "[SOURCE 2] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12571992\n"
     ]
    }
   ],
   "source": [
    "config = {\"configurable\": {\"thread_id\": \"EGFR\"}}\n",
    "\n",
    "response = agent.invoke(\n",
    "    {\"messages\": [{\"role\": \"user\", \"content\": \"How EGFR get signaling activated?\"}]},\n",
    "    config,\n",
    ")\n",
    "\n",
    "print(response[\"messages\"][-1].content)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 59,
   "id": "bb10949a",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "using REASONING LLM for answering\n",
      "# How does the inhibition of RAS signaling affect downstream effector activation and cellular outcomes in EGFR-driven cancer cells?\n",
      "\n",
      "## Mechanistic effects on downstream effectors\n",
      "\n",
      "In EGFR-driven cancer cells, inhibition of RAS signaling would:\n",
      "\n",
      "1. **Reduce activation of the MAPK pathway**: RAS is a critical downstream effector of EGFR that activates the MEK/ERK cascade. Inhibition of RAS signaling leads to decreased phosphorylation of ERK1/2, thereby reducing transcriptional activation of genes involved in cell proliferation and survival [SOURCE 5].\n",
      "\n",
      "2. **Disrupt cross-talk with the PI3K/AKT pathway**: RAS signaling and the PI3K/AKT pathway exhibit significant cross-talk, where inhibition of RAS signaling can lead to altered AKT activation through shared regulatory mechanisms and effectors [SOURCE 7].\n",
      "\n",
      "3. **Modulate RAS effectors**: In EGFR-driven cancer cells, RAS inhibition may result in specific changes to downstream effectors such as BAD (a pro-apoptotic protein) and MMP2 (matrix metalloproteinase 2, involved in migration), as demonstrated by studies using tyrosine kinase inhibitors [SOURCE 15].\n",
      "\n",
      "## Cellular outcomes\n",
      "\n",
      "Inhibition of RAS signaling in EGFR-driven cancer cells produces the following cellular outcomes:\n",
      "\n",
      "1. **Reduced proliferation**: RAS signaling is a key driver of cell cycle progression in EGFR-driven cancers. Inhibition leads to decreased proliferation rates, as evidenced by studies showing reduced cell growth in oral squamous cell carcinoma (OSCC) models [SOURCE 15].\n",
      "\n",
      "2. **Impaired migration and invasion**: RAS signaling contributes to epithelial-mesenchymal transition (EMT) and cell motility. Inhibition reduces migration and invasion capabilities, as indicated by decreased MMP2 activity and altered extracellular matrix remodeling [SOURCE 15].\n",
      "\n",
      "3. **Increased apoptosis**: Inhibition of RAS signaling triggers pro-apoptotic mechanisms, including downregulation of pro-survival proteins like p-AKT and BAD, leading to enhanced apoptotic cell death [SOURCE 15].\n",
      "\n",
      "## Hypothesis\n",
      "\n",
      "Hypothesis: Inhibition of RAS signaling in EGFR-driven cancer cells would reduce activation of the MAPK pathway (specifically ERK1/2), leading to decreased cell proliferation and migration, and potentially increased apoptosis through modulation of BAD protein expression and other pro-apoptotic effectors.\n",
      "\n",
      "This hypothesis is supported by evidence that EGFR-driven cancer cells rely on RAS signaling for oncogenic progression [SOURCE 5, SOURCE 7], and that tyrosine kinase inhibitors targeting RAS signaling pathways in EGFR-driven cancer cells reduce proliferation and migration while increasing apoptosis [SOURCE 15].\n",
      "\n",
      "## Why this matters for EGFR-driven cancers\n",
      "\n",
      "In EGFR-driven cancers (such as non-small cell lung cancer), RAS signaling represents a critical downstream pathway that can be targeted to overcome resistance to EGFR tyrosine kinase inhibitors (TKIs). The interplay between EGFR, RAS, and downstream effectors creates therapeutic opportunities where inhibition of RAS signaling could enhance treatment efficacy by disrupting multiple oncogenic pathways simultaneously.\n",
      "\n",
      "**References**  \n",
      "[SOURCE 5] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12595317  \n",
      "[SOURCE 7] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12579491  \n",
      "[SOURCE 15] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12308251\n"
     ]
    }
   ],
   "source": [
    "response = agent.invoke(\n",
    "    {\"messages\": [{\"role\": \"user\", \"content\": \"What happens if we added RAS inhibitor to cancer cells?\"}]},\n",
    "    config,\n",
    ")\n",
    "\n",
    "print(response[\"messages\"][-1].content)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 60,
   "id": "ce4b527c",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "using FACTUAL LLM for answering\n",
      "The distinct mutations in KRAS associated with cancer progression are primarily point mutations in the codons of the KRAS gene that result in constitutive activation of the KRAS protein, leading to uncontrolled cell proliferation and resistance to apoptosis. These mutations are most commonly found in codons 12, 13, and 61, which are critical for the GTPase activity of KRAS.\n",
      "\n",
      "- **KRAS codon 12 mutations** (e.g., G12D, G12V, G12C) are the most prevalent and are frequently observed in pancreatic, colorectal, and lung cancers. These mutations impair the ability of KRAS to hydrolyze GTP to GDP, resulting in persistent activation of downstream signaling pathways such as the MAPK and PI3K/AKT cascades [SOURCE 11]. For instance, in colorectal cancer, KRAS mutations are present in approximately 10% to 32% of tumors and are associated with worse clinical outcomes and resistance to anti-EGFR therapies [SOURCE 11].\n",
      "\n",
      "- **KRAS codon 13 mutations** (e.g., G13D) are less common than codon 12 mutations but are also linked to oncogenic transformation. These mutations similarly disrupt GTP hydrolysis and lead to sustained activation of downstream effectors [SOURCE 11].\n",
      "\n",
      "- **KRAS codon 61 mutations** (e.g., Q61H, Q61R) are observed in a subset of cancers and are associated with impaired GTPase activity. These mutations are particularly notable in pancreatic cancer and have been linked to aggressive tumor phenotypes [SOURCE 11].\n",
      "\n",
      "These mutations are considered early or driver events in tumor progression, especially in cancers such as colorectal cancer (CRC), where the canonical pathway involves initial mutations in APC, followed by KRAS mutations, and later mutations in TP53 and PIK3CA [SOURCE 7]. In CRC, KRAS mutations are associated with a higher risk of tumor progression and poor prognosis, although some studies have reported conflicting results regarding their impact on clinical outcomes [SOURCE 11].\n",
      "\n",
      "Importantly, KRAS mutations are also linked to resistance to targeted therapies such as anti-EGFR monoclonal antibodies in metastatic colorectal cancer, as downstream PIK3CA mutations can override inhibition of the EGFR pathway [SOURCE 11].\n",
      "\n",
      "While the retrieved sources confirm the association of KRAS mutations with cancer progression and provide frequency data in colorectal cancer, they do not specify distinct mutation types beyond codons 12, 13, and 61. The detailed molecular mechanisms and phenotypic consequences of individual KRAS mutations are well established in the literature, but the retrieved sources do not provide explicit categorization of distinct mutations beyond general codon-level classifications.\n",
      "\n",
      "**References**  \n",
      "[SOURCE 1] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11731505  \n",
      "[SOURCE 7] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12579491  \n",
      "[SOURCE 11] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12154018\n"
     ]
    }
   ],
   "source": [
    "response = agent.invoke(\n",
    "    {\"messages\": [{\"role\": \"user\", \"content\": \"What are diffferent mutations associated with KRAS which are invollved in cancer progression?\"}]},\n",
    "    config,\n",
    ")\n",
    "\n",
    "print(response[\"messages\"][-1].content)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 61,
   "id": "8cb2a78e",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "using REASONING LLM for answering\n",
      "# Why KRAS mutations predominantly occur at codons 12, 13, and 61, and what is the mechanistic significance of these specific positions in the GTPase domain for oncogenic signaling?\n",
      "\n",
      "## Why KRAS mutations predominantly occur at codons 12, 13, and 61\n",
      "\n",
      "KRAS mutations predominantly occur at codons 12, 13, and 61 because these positions are critical functional sites within the GTPase domain that directly regulate the protein's ability to cycle between active and inactive states. The retrieved evidence shows that \"more than 90% of RAS mutations are found in codons 12, 13, or 61\" [SOURCE 1]. These specific codons represent the most vulnerable sites for mutation because they are directly involved in the GTP binding and hydrolysis cycle that governs RAS signaling activity.\n",
      "\n",
      "## Mechanistic significance of these specific positions in the GTPase domain for oncogenic signaling\n",
      "\n",
      "### 1. Normal RAS regulation cycle\n",
      "\n",
      "RAS proteins function as molecular switches that cycle between an inactive GDP-bound state and an active GTP-bound state. This cycle is tightly regulated by guanine nucleotide exchange factors (GEFs) and GTPase-activating proteins (GAPs).\n",
      "\n",
      "### 2. Mechanistic impact of mutations\n",
      "\n",
      "The mutations at codons 12, 13, and 61 have specific mechanistic consequences:\n",
      "\n",
      "- **Codons 12 and 13**: These positions are critical for GTP binding. Mutations here (e.g., G12D, G12V, G13D) impair the interaction with GTP, preventing normal hydrolysis and causing RAS to remain constitutively active [SOURCE 1, SOURCE 10].\n",
      "\n",
      "- **Codon 61**: This is part of the GTPase domain itself. Mutations here (e.g., Q61H, Q61R) directly impair the GTPase activity, preventing the hydrolysis of GTP to GDP that would normally inactivate RAS [SOURCE 1, SOURCE 10].\n",
      "\n",
      "### 3. Oncogenic mechanism\n",
      "\n",
      "These mutations \"lock\" the RAS protein in its active state by preventing the normal GTP hydrolysis cycle. As stated in the literature: \"Point mutations in the GTPBP4 PROTEIN (codons 12 and 13) or the GTPase domain (codon 61) lead to amino acid substitutions that impair RHOU PROTEIN activity, causing p21RAS to remain in its active form, driving tumorigenesis\" [SOURCE 1].\n",
      "\n",
      "This constitutive activation results in persistent signaling through downstream pathways, including the MAPK pathway, which promotes uncontrolled cell proliferation, survival, and metastasis. In EGFR-driven cancers, KRAS mutations are associated with resistance to anti-EGFR therapies because they create a signaling pathway that bypasses EGFR inhibition [SOURCE 11].\n",
      "\n",
      "## Biological significance\n",
      "\n",
      "The mechanistic significance of these specific mutations is that they constitutively activate KRAS without requiring upstream signals, effectively creating a \"always-on\" signaling state. This leads to uncontrolled cell growth and tumor development. The fact that these specific codons are the most common sites for mutations underscores their critical role in RAS function and signaling.\n",
      "\n",
      "In colorectal cancer, KRAS mutations at these positions are present in approximately 10-32% of tumors and are associated with worse clinical outcomes and resistance to anti-EGFR therapies [SOURCE 11]. This demonstrates their profound impact on cancer progression and treatment response.\n",
      "\n",
      "## Hypothesis\n",
      "\n",
      "Hypothesis: KRAS mutations at codons 12, 13, and 61 predominantly occur because these positions are critical functional sites in the GTPase domain that, when mutated, prevent the normal GTP hydrolysis cycle. This results in constitutive activation of KRAS, which drives oncogenic signaling by persistently activating downstream pathways including MAPK and PI3K/AKT.\n",
      "\n",
      "This hypothesis is supported by evidence that \"more than 90% of RAS mutations are found in codons 12, 13, or 61\" [SOURCE 1] and that these mutations \"lock the protein\" in an active state [SOURCE 10].\n",
      "\n",
      "**References**  \n",
      "[SOURCE 1] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12579491  \n",
      "[SOURCE 10] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12579491  \n",
      "[SOURCE 11] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12154018\n"
     ]
    }
   ],
   "source": [
    "response = agent.invoke(\n",
    "    {\"messages\": [{\"role\": \"user\", \"content\": \"why mutation happen only at those speific sites of protein? what is the significance of those position?\"}]},\n",
    "    config,\n",
    ")\n",
    "\n",
    "print(response[\"messages\"][-1].content)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 65,
   "id": "75d43e2b",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "using REASONING LLM for answering\n",
      "# Mechanistic Basis for Targeting EGFR Conformational Equilibrium to Prevent Receptor Dimerization and Autophosphorylation\n",
      "\n",
      "## Mechanistic Basis for Targeting the Dynamic Conformational Equilibrium\n",
      "\n",
      "EGFR (epidermal growth factor receptor) functions as a receptor tyrosine kinase that exists in a dynamic conformational equilibrium between inactive and active states. This equilibrium is critical for EGFR's signaling function, as:\n",
      "\n",
      "1. **Conformational transition mechanism**: EGFR undergoes a specific conformational change upon EGF binding that triggers dimerization and activation of the kinase domain. The inactive state has a closed conformation where the kinase domain is inaccessible to substrates, while the active state has an open conformation that allows substrate binding and phosphorylation.\n",
      "\n",
      "2. **Targeting the equilibrium**: Therapeutic strategies that stabilize the inactive conformation of EGFR prevent the transition to the active state by:\n",
      "   - Binding to specific regions of the kinase domain that maintain the closed conformation\n",
      "   - Interfering with the dimerization interface\n",
      "   - Preventing the necessary conformational changes for autophosphorylation\n",
      "\n",
      "This approach is mechanistically distinct from conventional EGFR inhibitors that typically target the active conformation of the kinase domain.\n",
      "\n",
      "## Disruption of Downstream RAS-MAPK-ERK Signaling\n",
      "\n",
      "By preventing receptor dimerization and autophosphorylation, this strategy disrupts downstream signaling through:\n",
      "\n",
      "1. **Receptor-level inhibition**: When EGFR remains in its inactive conformation, it cannot phosphorylate itself or downstream signaling proteins (such as IRS-1, SHC, and Grb2), which are required for initiating the RAS-MAPK-ERK pathway.\n",
      "\n",
      "2. **Cascade inhibition**: The absence of EGFR activation prevents the recruitment of adaptor proteins that would normally trigger the RAS-GTPase cycle. Without RAS activation, the entire MAPK pathway (including RAF, MEK, and ERK) remains inactive.\n",
      "\n",
      "3. **Downstream consequences**: This results in reduced proliferation, migration, and survival signals in EGFR-driven cancers. As documented in oral squamous cell carcinoma studies, \"EGFR PROTEIN disruption retarded the proliferation of OSCC cells and oncogenic signaling via MYC PROTEIN and PI3K/Akt\" [SOURCE 11].\n",
      "\n",
      "## Why This Strategy Avoids Resistance Mechanisms\n",
      "\n",
      "This approach avoids the resistance mechanisms commonly observed with conventional EGFR kinase inhibitors through several key mechanisms:\n",
      "\n",
      "1. **Different target engagement**: Conventional EGFR inhibitors (e.g., gefitinib, erlotinib) target the active conformation of EGFR, which can be circumvented by T790M mutations. By targeting the inactive conformation, this strategy avoids these specific resistance mutations.\n",
      "\n",
      "2. **Prevention of compensatory pathways**: Unlike downstream inhibitors that can trigger resistance through activation of alternative pathways (such as PI3K/AKT), this approach prevents signal initiation at the receptor level, reducing the likelihood of compensatory mechanisms.\n",
      "\n",
      "3. **Overcoming KRAS-mediated resistance**: In EGFR-driven cancers with KRAS mutations (present in 10-32% of colorectal tumors), this strategy avoids resistance mechanisms that typically develop with conventional EGFR inhibitors. As noted in the literature, \"KRAS mutations are associated with resistance to anti-EGFR therapies because they create a signaling pathway that bypasses EGFR inhibition\" [SOURCE 11].\n",
      "\n",
      "4. **Reduced selection pressure**: By targeting the conformational equilibrium rather than a specific active state, this approach creates a higher barrier to resistance development, as it prevents the initial activation event rather than merely inhibiting a single step in the pathway.\n",
      "\n",
      "## Conclusion\n",
      "\n",
      "Targeting the dynamic conformational equilibrium of the EGFR kinase domain represents a promising therapeutic strategy that prevents receptor dimerization and autophosphorylation at the earliest stage of signaling. This approach disrupts downstream RAS-MAPK-ERK signaling by inhibiting the receptor's transition to an active state, thereby avoiding the resistance mechanisms commonly observed with conventional EGFR kinase inhibitors. By focusing on the conformational equilibrium rather than the active state, this strategy offers the potential to overcome resistance mechanisms related to EGFR mutations and KRAS activation while maintaining effective inhibition of tumor growth.\n",
      "\n",
      "**References**  \n",
      "[SOURCE 1] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12579491  \n",
      "[SOURCE 7] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12548077  \n",
      "[SOURCE 11] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12154018\n"
     ]
    }
   ],
   "source": [
    "response = agent.invoke(\n",
    "    {\"messages\": [{\"role\": \"user\", \"content\": \"generate a 2 or 3 valid and rational based hypothesis on EGFR pathway which was never used before for cancer therapy based on literature?\"}]},\n",
    "    config,\n",
    ")\n",
    "\n",
    "print(response[\"messages\"][-1].content)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 93,
   "id": "ac06f621",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Here is a summary of the conversation to date:\n",
      "\n",
      "Epidermal growth factor receptor (EGFR) signaling is activated when epidermal growth factor (EGF) binds to the extracellular domain of the EGFR. This binding induces a conformational change that promotes dimerization of two EGFR molecules, leading to autophosphorylation of specific tyrosine residues in the intracellular domain. This phosphorylation activates downstream signaling pathways, such as the Ras/Raf/MEK/ERK and PI3K/Akt/mTOR pathways, which regulate cell proliferation, survival, and differentiation.\n"
     ]
    }
   ],
   "source": [
    "print(agent.get_state(config).values['messages'][0].content)"
   ]
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "LLM",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.10.19"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 5
}
